- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07272954
Efectos del bloqueo del ganglio estrellado guiado por ultrasonidos y la estimulación transcutánea del nervio vago auricular sobre la calidad del sueño tras la mastectomía radical por cáncer de mama
Efectos del Bloqueo del Ganglio Estrellado Guiado por Ultrasonido y la Estimulación Transcutánea del Nervio Vago Auricular sobre la Calidad del Sueño Tras la Mastectomía Radical por Cáncer de Mama
This study aims to design a prospective, randomized, controlled, dual-center, non-inferiority trial to compare the effects of ultrasound-guided sympathetic ganglion block (SGB) and transcutaneous auricular vagus nerve stimulation (taVNS) on sleep quality following radical mastectomy for breast cancer. The objective is to explore whether non-invasive neuromodulation for sleep is non-inferior to invasive neuromodulation. Participants will be randomly assigned to receive either SGB or taVNS treatment. Sleep quality will be assessed using an actigraphy device and sleep scales within four days post-surgery, and the incidence of sleep disturbances will be followed up within 30 days post-surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Mingzi An
- Número de teléfono: +8618035193080
- Correo electrónico: anmingzizi@163.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- aged 18-80 years who underwent radical surgery for breast cancer
- ASA I-III
Exclusion Criteria:
- 1. Patients with coagulation dysfunction;
- Patients with suspected regional infection leading to severe nerve damage in the affected limb;
- Patients with congenital heart disease, coronary artery disease, myocardial infarction, severe cardiac conduction block, or those with implanted cardiac pacemakers;
- Patients with severe neurological disorders such as cerebral infarction, cerebral hemorrhage, or stroke;
- Patients with pain, lesions, infections, or unresolved external ear trauma in the area near the external ear;
- Patients with severe mental illness or a history of substance abuse related to analgesics or psychiatric medications;
- Patients with allergies to local anesthetics such as lidocaine or ropivacaine, as well as to general anesthetics;
- Patients and their families who refuse surgical anesthesia and those unable to complete the survey questionnaire.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Stellate Ganglion Block(SGB)
Before the induction of anesthesia in the operating room, a skilled anesthesiologist performed a SGB under sterile conditions using real-time ultrasound in a blind grouping manner. |
Before the induction of anesthesia in the operating room, a skilled anesthesiologist performed a SGB under sterile conditions using real-time ultrasound in a blind grouping manner. The patient was positioned supine with the neck slightly rotated to the left. A linear probe (6-13 MHz) was placed on the neck to clearly visualize the carotid artery, internal jugular vein, vertebral artery, vagus nerve, thyroid gland, esophagus, scalene muscles, and the anterior scalene muscle at the C6 level. Subsequently, a 48mm, 20-gauge needle was inserted in a "plane" direction into the prevertebral fascia of the anterior scalene muscle. After the needle tip penetrated the prevertebral fascia and negative pressure aspiration was confirmed, 3ml of 0.5% ropivacaine was injected, and the diffusion of the local anesthetic was observed under ultrasound guidance. |
|
Experimental: transcutaneous vagus nerve stimulation(taVNS)
Three stimulations of transcutaneous auricular vagus nerve stimulation (taVNS) were administered to the patients |
Three stimulations of transcutaneous auricular vagus nerve stimulation (taVNS) were administered to the patients: ① According to the manufacturer's recommendations and previous studies [32], the initial adjustment required electrical stimulation to penetrate the skin barrier. The first intervention was conducted one day prior to the surgery, with an initial electrical stimulation frequency set at 30 Hz and a pulse width of 300 μs. The frequency and pulse width were adjusted based on the individual patient's sensations until the maximum tolerable current stimulation was reached without discomfort, lasting for 30 minutes; ② The second intervention occurred immediately after the patient was connected to the monitoring equipment in the operating room, once their vital signs were confirmed to be within normal ranges. The same stimulation frequency as the first intervention was applied for 30 minutes; ③ The third intervention was administered in the recovery room after the patient's surgery |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total Sleep Time on the First Night Post-Surgery
Periodo de tiempo: the First Night Post-Surgery
|
Total Sleep Time Monitored by Actigraphy on the First Night Post-Surgery |
the First Night Post-Surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total sleep time from the second to the fourth night post-surgery
Periodo de tiempo: the second to the fourth night post-surgery
|
Total sleep time each night from the second to the fourth night post-surgery by Actigraphy |
the second to the fourth night post-surgery
|
|
Assessment of sleep quality during the first four nights postoperatively
Periodo de tiempo: during the first four nights postoperatively
|
Assessment of sleep quality using the Richards-Campbell Sleep Questionnaire(RCSQ) sleep questionnaire during the first four nights postoperatively. The total score is 150 points, with the minimum score being 0 points. A higher score indicates better postoperative sleep quality. |
during the first four nights postoperatively
|
|
sleep quality and the incidence of sleep disturbances on the 30th postoperative day
Periodo de tiempo: On the 30th postoperative day
|
On the 30th postoperative day, the Pittsburgh Sleep Quality Index (PSQI) will be used to assess subjective sleep quality and the incidence of sleep disturbances.The score ranges from 0 to 21 points, with higher scores indicating worse postoperative sleep quality.A score greater than 7 indicates the presence of sleep disturbance. |
On the 30th postoperative day
|
|
The incidence of all complications and mortality within 72 hours postoperatively
Periodo de tiempo: within 72 hours postoperatively
|
The incidence of all complications and mortality within 72 hours postoperatively |
within 72 hours postoperatively
|
|
Quality of Recovery score at 24 hours postoperatively (QoR-15).
Periodo de tiempo: at 24 hours postoperatively
|
Quality of Recovery score at 24 hours postoperatively (QoR-15). The score ranges from 0 to 150 points, with higher scores indicating better postoperative recovery quality. |
at 24 hours postoperatively
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2025-LP-777
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .